Lexaria Bioscience Corp. develops and licenses DehydraTECH, a patented oral drug delivery formulation and processing platform designed to improve how active pharmaceutical ingredients enter the bloodstream. News about LEXX centers on GLP-1 drug delivery research, DehydraTECH-semaglutide compositions, preclinical and human study updates, intellectual property activity, and pharmaceutical partner evaluations under material transfer arrangements.
Company updates also cover Lexaria's investor communications, oral drug delivery market commentary, and applications of DehydraTECH across pharmaceuticals, nutraceuticals, over-the-counter products, and consumer formats. Recurring themes include bioabsorption, tolerability, blood-brain-barrier delivery, research laboratory activity, and the company's IP licensing business model.
Lexaria Bioscience (LEXX) reported an improved cash position after raising US$7.9 million from an Australian tax refund and institutional financing.
The institutional financing was priced at US$12.92 per share, and with 2.1 million shares outstanding, Lexaria reports about US$4.60 per share in current cash on hand. Management states that this fresh capital extends the company’s cash runway through 2027 and that there is no intention to pursue additional equity or debt financings in 2026. Lexaria also expects future business development relationships to fund a greater share of 2027 R&D costs and plans to provide updates on its 2026 and 2027 R&D programs.
Lexaria Bioscience (LEXX) has closed the previously announced cash exercise of certain outstanding warrants for an aggregate 453,969 common shares at a reduced exercise price of $12.92 per share, generating approximately $5.9 million in gross proceeds before fees.
In connection with the exercise, Lexaria issued new unregistered Series A and Series B warrants, each series covering up to 453,969 shares at an exercise price of $12.67 per share. The Series A warrants are immediately exercisable and expire five years after the effective date of a planned resale registration statement, while the Series B warrants are immediately exercisable and expire eighteen months after that effective date. Lexaria expects to use the net proceeds for working capital and general corporate purposes.
Lexaria Bioscience (LEXX) entered definitive agreements for the immediate cash exercise of 453,969 outstanding warrants at a reduced exercise price of $12.92 per share. Closing is expected on or about September 9, 2026, subject to customary conditions.
The warrant exercises are expected to generate approximately $5.9 million in gross proceeds before fees, to be used for working capital and general corporate purposes. In exchange, Lexaria will issue new unregistered Series A and Series B warrants for up to 453,969 shares each, both exercisable immediately at $12.67 per share, with five‑year and eighteen‑month terms, respectively, from the effective date of a planned resale registration statement. The CEO also cites a recently received $2.6 million Australian tax rebate as additional funding for 2027 operations and R&D.
Lexaria Bioscience (LEXX) will participate in the 28th Annual H.C. Wainwright Global Investment Conference in New York City from September 14–16, 2026. CEO Richard Christopher will deliver a company presentation and hold one-on-one investor meetings, with the presentation also accessible online via a provided link.
Lexaria Bioscience (NASDAQ:LEXX) announced receipt of an Australian R&D Tax Incentive cash rebate of AUD$3,666,611.98 (about USD$2.6 million), deposited into its wholly owned subsidiary Lexaria (AU) Pty Ltd. The rebate relates to Lexaria’s 12‑week chronic GLP-1-H24-4 human study conducted in Australia in 2025.
According to Lexaria, the rebate followed a review confirming compliance with the Australian R&D Tax Incentive Program and will be used to fund future R&D in Australia. The USD$2.6 million was not included in previously filed financial statements or cash runway projections and will be reflected in the upcoming annual 10-K. Lexaria also highlighted that this funding was obtained without issuing equity and that the company remains debt-free.
Lexaria Bioscience (NASDAQ:LEXX) reported pharmacokinetic results from its 2026 Animal Study #2 in dogs, evaluating DehydraTECH 3.0 (DHT3.0) tablet and capsule formulations of next‑generation GLP‑1 drugs amycretin and retatrutide versus prior DehydraTECH 2.0 (DHT2.0) formulations and intravenous dosing benchmarks.
For amycretin, the best DHT3.0 tablet (ALT 2) achieved an AUC D of 4,967.78 hr*ng/mL/(mg/kg) and absolute bioavailability of 1.65%, a 481.14% increase over the DHT2.0 reference tablet and more than double the 0.70% absolute bioavailability reported in published oral amycretin research without DehydraTECH. All three DHT3.0 amycretin tablets exceeded the DHT2.0 reference tablet, and DHT3.0 with sodium caprate outperformed SNAC-enabled versions.
For retatrutide, all three DHT3.0 tablets and all three DHT3.0 capsules surpassed their respective DHT2.0 SNAC-based references. The top DHT3.0 retatrutide tablet (ALT 2) showed a 4,552.20% absorption improvement versus the reference tablet, while the best DHT3.0 capsules (ALT 1 and ALT 2) in 7 mg format reached 0.26% absolute bioavailability compared to intravenous dosing. Lexaria stated that these findings support its strategic partnering efforts for oral delivery of next‑generation GLP‑1 drugs, while emphasizing that further, including human, studies are required.
Lexaria Bioscience (NASDAQ:LEXX) has entered into a Material Transfer Agreement with PegBio to evaluate Lexaria's patented DehydraTECH oral drug delivery technology with a proprietary PegBio GLP-1 molecule under development for the GLP-1 market. PegBio will supply the GLP-1 compound, which Lexaria will formulate with DehydraTECH and test for pharmacokinetic performance in animal studies.
The arrangement is independent from Lexaria's existing MTA with another pharmaceutical company. PegBio has a commercial GLP-1 injection approved in China since November 2025 and additional GLP-1 candidates up to Phase II in China and the USA. Lexaria plans to provide an update after the planned studies, including any decisions on potential technology licensing or other business arrangements.
Lexaria Bioscience (Nasdaq:LEXX) will implement a 1-for-15 reverse stock split of its common shares effective 12:01 a.m. EST on August 3, 2026, aiming to increase its share price to regain compliance with Nasdaq’s $1.00 minimum bid requirement under Listing Rule 5550(a)(2).
The split will consolidate approximately 24.79 million issued shares into about 1.65 million shares, with fractional shares rounded up. Authorized shares will decrease from 220 million to about 14.67 million, without changing par value, leaving shareholder ownership percentages unchanged. Options and warrants and their exercise prices will be adjusted proportionally, and LEXX will retain its Nasdaq symbol with a new CUSIP.
Lexaria Bioscience (NASDAQ:LEXX) reported strong business development activity following the 2026 BIO International Convention in San Diego. The company held numerous meetings with potential partners, from small tech firms to large pharmaceutical companies, mainly focused on GLP-1 drug applications and its DehydraTECH technology.
According to Lexaria, discussions emphasized balancing weight-loss efficacy with safety and tolerability, aligning with DehydraTECH capabilities. The company also noted renewed interest in DehydraTECH-CBD and DehydraTECH-nicotine, where it has prior R&D experience, and plans to share further updates when appropriate.
Lexaria Bioscience (NASDAQ:LEXX) began dosing on June 14, 2026 in Human Pilot Study #7 (GLP-1-H26-7), a 5-week trial of two oral DehydraTECH-semaglutide (DHT-sema) formulations versus Novo Nordisk’s Wegovy tablets.
The three-arm study compares SNAC-inclusive DHT-sema tablets and capsules with Wegovy under fasted conditions, aims to reach steady-state semaglutide levels, evaluates safety, tolerability and pharmacokinetics, tests new tablet properties modeled on Rybelsus/Wegovy, and is fully funded from existing resources.